Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
申请人:Glionova AB
公开号:EP3064205A1
公开(公告)日:2016-09-07
The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 (NSC13316, (2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.
本发明涉及2,4-二取代喹啉衍生物Vacquinol-1(NSC13316,(2-(4-氯苯基)喹啉-4-基)(哌啶-2-基)甲醇)的某些同分异构体形式,用于治疗全身性癌症,以及包含所述2,4-二取代喹啉衍生物Vacquinol-1的同分异构体形式的制药组合物,用于所述治疗。